Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

MRD Testing in Hematologic Malignancies

December 6th 2017

Phase III Data for Relapsed/Refractory Myeloma

December 6th 2017

Key Studies in Newly-Diagnosed Multiple Myeloma

December 6th 2017

Daratumumab for Smoldering Myeloma

December 6th 2017

KRd for High-Risk Smoldering Myeloma

December 6th 2017

AML Studies: BiTE Antibodies and Age for Transplant

December 6th 2017

AML Studies: FLT3 Inhibitors

December 6th 2017

Acute Myeloid Leukemia: Novel Targeted Therapies

December 6th 2017

NHL Studies: CAR T Therapy, Rituximab Maintenance, & PD-L1

December 6th 2017

New Data for Mantle Cell Lymphoma

December 6th 2017

Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVD

December 6th 2017

Pre-Conference Perspectives on Hematologic Malignancies

December 6th 2017

Ibrutinib Combo Improves PFS in Waldenstrom Macroglobulinemia

December 6th 2017

The combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) improved progression-free survival versus rituximab alone in patients with Waldenström macroglobulinemia.

Expert Emphasizes Appropriate Diagnosis, Staging of T-Cell Lymphomas

December 1st 2017

Sunita D. Nasta, MD, compares the biology of peripheral and cutaneous T-cell lymphomas and offered advice on the optimal therapeutic approaches for either disease with novel agents.

FDA Grants Mogamulizumab Priority Review for CTCL

November 28th 2017

The FDA has granted a priority review to a biologics license application for mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Dr. O'Connor on the Role of Obinutuzumab in Follicular Lymphoma

November 28th 2017

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the role of obinutuzumab (Gazyva) in the treatment of patients with follicular lymphoma.

Dr. Winter Discusses Copanlisib in Follicular Lymphoma

November 18th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.

Dr. Epperla on FDA Approval of Frontline Obinutuzumab in Follicular Lymphoma

November 16th 2017

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

FDA Approves Frontline Obinutuzumab for Follicular Lymphoma

November 16th 2017

The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma.

Brentuximab Vedotin Nears European Approval for CTCL

November 15th 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin (Adcetris) in adults with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.